Faster by Design: What’s Driving the Acceleration of Drug Development Timelines?
Information
Accelerated timelines are no longer the exception – they’re becoming the norm across the pharmaceutical industry. From oncology to rare diseases, an increasing number of molecules are receiving conditional or expedited approvals, often at earlier stages of development. This trend is reshaping expectations not only for clinical progress but also for chemistry, manufacturing, and controls (CMC), where development windows are tightening significantly. In fact, nearly two-thirds of recent FDA novel drug approvals have occurred under some form of accelerated pathway. In this panel discussion, industry leaders will explore the forces driving this shift – from regulatory evolution to economic pressures – and how companies are adapting. We’ll discuss the operational, strategic, and scientific implications of accelerated timelines and share practical insights on how to stay competitive without compromising quality.
